Effects of a ketogenic diet in overweight women with polycystic ovary syndrome - PubMed (original) (raw)

Clinical Trial

Effects of a ketogenic diet in overweight women with polycystic ovary syndrome

Antonio Paoli et al. J Transl Med. 2020.

Abstract

Background: Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women during reproductive age. It is characterised clinically by oligo-ovulation or anovulation, hyper-androgenism, and the presence of polycystic ovaries. It is associated with an increased prevalence of metabolic syndrome, cardiovascular disease and type 2 diabetes. The onset of PCOS has been associated to several hereditary and environmental factors, but insulin resistance plays a key pathogenetic role. We sought to investigate the effects of a ketogenic diet (KD) on women of childbearing age with a diagnosis of PCOS.

Methods: Fourteen overweight women with diagnosis of PCOS underwent to a ketogenic Mediterranean diet with phyoextracts (KEMEPHY) for 12 week. Changes in body weight, body mass index (BMI), fat body mass (FBM), lean body mass (LBM), visceral adipose tissue (VAT), insulin, glucose, HOMA-IR, total cholesterol, low density lipoprotein (LDL), high density lipoprotein (HDL), triglycerides (TGs), total and free testosterone, luteinizing hormone (LH), follicle stimulating hormone (FSH); dehydroepiandrosterone sulfate (DHEAs), estradiol, progesterone, sex hormone binding globulin (SHBG) and Ferriman Gallwey score were evaluated.

Results: After 12 weeks, anthropometric and body composition measurements revealed a significant reduction of body weight (- 9.43 kg), BMI (- 3.35), FBM (8.29 kg) and VAT. There was a significant, slightly decrease of LBM. A significant decrease in glucose and insulin blood levels were observed, together with a significant improvement of HOMA-IR. A significant decrease of triglycerides, total cholesterol and LDL were observed along with a rise in HDL levels. The LH/FSH ratio, LH total and free testosterone, and DHEAS blood levels were also significantly reduced. Estradiol, progesterone and SHBG increased. The Ferriman Gallwey Score was slightly, although not significantly, reduced.

Conclusions: Our results suggest that a KD may be considered as a valuable non pharmacological treatment for PCOS. Longer treatment periods should be tested to verify the effect of a KD on the dermatological aspects of PCOS. Trial registration Clinicaltrial.gov, NCT04163120, registrered 10 November 2019, retrospectively registered, https://clinicaltrials.gov.

Keywords: Hyperinsulinemia; Ketogenic diet; Ketone bodies; LCKD; Low carbohydrate diet; Overweight; PCOS.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1

Fig. 1

Flow chart of experimental design. Recruitment of patients. Further details are reported in the text

Fig. 2

Fig. 2

Changes in anthropometric variables after 12 weeks of KD. BMI body mass index, FBM fat body mass, LBM mean body mass. Standard deviation is represented in the figure. ***p < 0.0001; **p = 0.0015; *p = 0.0205

Fig. 3

Fig. 3

Changes in hormonal variables after 12 weeks of KD. LH luteinizing hormone, FSH follicle stimulating hormone, DHEAs dehydroepiandrosterone sulfate, SHBG sex hormone binding globulin. Standard deviation is represented in the figure. ***p < 0.0001; **#p = 0.009; **P = 0.0082; *p = 0.0258

References

    1. Trikudanathan S. Polycystic ovarian syndrome. Med Clin North Am. 2015;99(1):221–235. doi: 10.1016/j.mcna.2014.09.003. - DOI - PubMed
    1. Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol. 2013;6:1–13. doi: 10.2147/CLEP.S37559. - DOI - PMC - PubMed
    1. Palomba S, Falbo A, Chiossi G, Muscogiuri G, Fornaciari E, Orio F, et al. Lipid profile in nonobese pregnant women with polycystic ovary syndrome: a prospective controlled clinical study. Steroids. 2014;88:36–43. doi: 10.1016/j.steroids.2014.06.005. - DOI - PubMed
    1. El Hayek S, Bitar L, Hamdar LH, Mirza FG, Daoud G. Poly cystic ovarian syndrome: an updated overview. Front Physiol. 2016;7:124. doi: 10.3389/fphys.2016.00124. - DOI - PMC - PubMed
    1. Larner J, Brautigan DL, Thorner MO. D-chiro-inositol glycans in insulin signaling and insulin resistance. Mol Med. 2010;16(11–12):543–552. doi: 10.2119/molmed.2010.00107. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources